SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2024 · 69 positions · Total reported value $435.75M · Top-10 concentration 48.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 69 equity positions with a combined reported value of $435.75M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.0% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were NUVL ($38.00M), MRUS ($31.75M), INSM ($25.38M). By sector, the heaviest allocations are Health Care 59.5%, Industrials 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+4.2pp) and away from Other (-3.8pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 69% of names.

The largest new positions opened in Q3 2024 were CNTA ($11.91M), PTGX ($6.60M), BNTX ($3.10M).

Of the 18 positions fully exited versus the prior quarter, the largest were MORF ($16.57M), MIRM ($2.71M), JSPR ($2.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • CNTA CENTESSA PHARMACEUTICALS PLC · $11.91M
  • PTGX PROTAGONIST THERAPEUTICS INC · $6.60M
  • BNTX BIONTECH SE · $3.10M
  • RLAY RELAY THERAPEUTICS INC · $2.97M
  • ZVRA ZEVRA THERAPEUTICS INC · $2.43M
  • BIOA BIOAGE LABS INC · $2.08M
  • UNCY UNICYCIVE THERAPEUTICS INC · $1.63M
  • XNCR XENCOR INC · $1.52M

Fully Exited (vs previous quarter)

  • MORF MORPHIC HLDG INC · prev qtr: $16.57M
  • MIRM MIRUM PHARMACEUTICALS INC · prev qtr: $2.71M
  • JSPR Jasper Therapeutics Inc · prev qtr: $2.49M
  • ENGN ENGENE THERAPEUTICS INC · prev qtr: $2.49M
  • FULC FULCRUM THERAPEUTICS INC · prev qtr: $2.47M
  • STOK STOKE THERAPEUTICS INC · prev qtr: $1.91M
  • MGNX MACROGENICS INC · prev qtr: $1.57M
  • ZURA ZURA BIO LTD · prev qtr: $1.15M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 59.5%
Other 40.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 371.44K $38.00M 8.72%
8.72%
Reduce
2 635.44K $31.75M 7.29%
7.29%
Add
3 347.69K $25.38M 5.83%
5.83%
Add
4 475.56K $21.84M 5.01%
5.01%
Reduce
5 6.95M $18.96M 4.35%
4.35%
Reduce
6 639.84K $18.36M 4.21%
4.21%
Add
7 470.56K $16.02M 3.68%
3.68%
Add
8 255.58K $13.39M 3.07%
3.07%
Add
9 1.22M $13.19M 3.03%
3.03%
Add
10 167.11K $12.23M 2.81%
2.81%
Reduce
11 744.59K $11.91M 2.73%
2.73%
New
12 901.13K $11.44M 2.63%
2.63%
Reduce
13 1.10M $11.27M 2.59%
2.59%
Add
14 3.69M $10.55M 2.42%
2.42%
Add
15 348.87K $10.04M 2.30%
2.30%
Add
16 35.77K $9.84M 2.26%
2.26%
Reduce
17 1.80M $8.18M 1.88%
1.88%
Add
18 378.75K $7.29M 1.67%
1.67%
Add
19 60.50K $6.91M 1.59%
1.59%
Add
20 574.56K $6.65M 1.53%
1.53%
Add
21 146.66K $6.60M 1.51%
1.51%
New
22 51.24K $6.40M 1.47%
1.47%
Add
23 3.56M $6.34M 1.46%
1.46%
Add
24 1.65M $6.27M 1.44%
1.44%
Add
25 1.80M $5.65M 1.30%
1.30%
Add
26 5.65M $5.57M 1.28%
1.28%
Add
27 455.08K $5.43M 1.25%
1.25%
Reduce
28 513.37K $5.36M 1.23%
1.23%
Add
29 461.66K $5.32M 1.22%
1.22%
Add
30 627.55K $5.15M 1.18%
1.18%
Add
31 103.86K $5.10M 1.17%
1.17%
Add
32 99.57K $4.98M 1.14%
1.14%
Hold
33 145.00K $4.93M 1.13%
1.13%
Reduce
34 124.35K $4.14M 0.95%
0.95%
Add
35 19.94K $3.87M 0.89%
0.89%
Add
36 67.05K $3.86M 0.89%
0.89%
Hold
37 1.44M $3.24M 0.74%
0.74%
Add
38 457.74K $3.19M 0.73%
0.73%
Reduce
39 26.08K $3.10M 0.71%
0.71%
New
40 70.52K $3.09M 0.71%
0.71%
Hold
41 419.24K $2.97M 0.68%
0.68%
New
42 1.12M $2.85M 0.65%
0.65%
Add
43 1.50M $2.72M 0.62%
0.62%
Hold
44 1.50M $2.60M 0.60%
0.60%
Add
45 350.00K $2.43M 0.56%
0.56%
New
46 167.99K $2.24M 0.52%
0.52%
Reduce
47 100.00K $2.08M 0.48%
0.48%
New
48 4.00M $1.63M 0.37%
0.37%
New
49 482.57K $1.61M 0.37%
0.37%
Reduce
50 75.51K $1.52M 0.35%
0.35%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2024-Q3?

In its 2024-Q3 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 69 equity positions worth $435.75M in aggregate; its largest disclosed positions were NUVL ($38.00M), MRUS ($31.75M), INSM ($25.38M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $435.75M of long equity holdings across 69 positions as of 2024-Q3. Top-10 holdings account for 48.0% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →